Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction to: IOERT versus external beam electrons for boost radiotherapy in stage I/II breast cancer: 10-year results of a phase III randomized study.
Ciabattoni A, Gregucci F, Fastner G, Cavuto S, Spera A, Drago S, Ziegler I, Mirri MA, Consorti R, Sedlmayer F. Ciabattoni A, et al. Among authors: mirri ma. Breast Cancer Res. 2021 Apr 28;23(1):50. doi: 10.1186/s13058-021-01432-9. Breast Cancer Res. 2021. PMID: 33910604 Free PMC article. No abstract available.
Resilience in Radiotherapy Services During the COVID-19 Emergency: Collaboration Between the Regional Radiation Oncology Departments of Lazio, Abruzzo and Molise.
DE Angeli M, Anzellini D, Arcangeli G, Bianchi P, Chiostrini C, Ciabattoni A, Costa AM, Del Bufalo S, Deodato F, DE Paula U, D'Ugo C, Fedele F, Genovesi D, Gentile P, Gravina GL, Marmiroli L, Mirri MA, Ramella S, Rosetto ME, Santarelli M, Tombolini V, Trodella L, Valentini V, Osti MF, D'Angelillo RM. DE Angeli M, et al. Among authors: mirri ma. Anticancer Res. 2021 Jul;41(7):3561-3565. doi: 10.21873/anticanres.15143. Anticancer Res. 2021. PMID: 34230151
Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions.
Fellin G, Mirri MA, Santoro L, Jereczek-Fossa BA, Divan C, Mussari S, Ziglio F, La Face B, Barbera F, Buglione M, Bandera L, Ghedi B, Di Muzio NG, Losa A, Mangili P, Nava L, Chiarlone R, Ciscognetti N, Gastaldi E, Cattani F, Spoto R, Vavassori A, Giglioli FR, Guarneri A, Cerboneschi V, Mignogna M, Paoluzzi M, Ravaglia V, Chiumento C, Clemente S, Fusco V, Santini R, Stefanacci M, Mangiacotti FP, Martini M, Palloni T, Schinaia G, Lazzari G, Silvano G, Magrini S, Ricardi U, Santoni R, Orecchia R. Fellin G, et al. Among authors: mirri ma. Br J Radiol. 2016 Sep;89(1065):20150981. doi: 10.1259/bjr.20150981. Epub 2016 Jul 7. Br J Radiol. 2016. PMID: 27384381 Free PMC article.
Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme.
Metro G, Fabi A, Mirri MA, Vidiri A, Pace A, Carosi M, Russillo M, Maschio M, Giannarelli D, Pellegrini D, Pompili A, Cognetti F, Carapella CM. Metro G, et al. Among authors: mirri ma. Cancer Chemother Pharmacol. 2010 Jan;65(2):391-7. doi: 10.1007/s00280-009-1155-x. Epub 2009 Oct 22. Cancer Chemother Pharmacol. 2010. PMID: 19847425 Clinical Trial.
17 results